A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.

@article{Welsh2012ARD,
  title={A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.},
  author={Robert C. Welsh and Sunil V. Rao and Uwe Zeymer and Vivian P. Thompson and K K G Huber and Janusz Kochman and Matthew W. McClure and Daniel D. Gretler and Deepak L Bhatt and C Michael Gibson and Dominick J. Angiolillo and Paul A Gurbel and Lisa G. Berdan and Gayle Paynter and Sergio Leonardi and Mina Madan and William J. French and Robert A. Harrington},
  journal={Circulation. Cardiovascular interventions},
  year={2012},
  volume={5 3},
  pages={
          336-46
        }
}
BACKGROUND We evaluated the safety, efficacy, and tolerability of elinogrel, a competitive, reversible intravenous and oral P2Y(12) inhibitor that does not require metabolic activation, in patients undergoing nonurgent percutaneous coronary intervention. METHODS AND RESULTS In a randomized, double-blind, dose-ranging phase 2b trial, 652 patients received either 300 or 600 mg of clopidogrel pre-percutaneous coronary intervention followed by 75 mg daily or 80 or 120 mg of IV elinogrel followed… CONTINUE READING
Highlighted Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES